Patient Self-Reported Adherence to Ritonavir-Boosted Darunavir Combined With Either Raltegravir or Tenofovir Disoproxil Fumarate/Emtricitabine in the NEAT001/ANRS143 Trial

BACKGROUND: The NEAT001/ANRS143 trial demonstrated noninferiority of ritonavir-boosted darunavir combined with either raltegravir (RAL + DRV/r) or tenofovir disoproxil fumarate/emtricitabine (TDF/FTC + DRV/r) in HIV-positive, antiretroviral-naive adults. In post hoc analyses, however, RAL + DRV/r sh...

詳細記述

保存先:
書誌詳細
出版年:J Acquir Immune Defic Syndr
主要な著者: Ammassari, Adriana, Stöhr, Wolfgang, Antinori, Andrea, Molina, Jean-Michel, Schwimmer, Christine, Domingo, Pere, Thalme, Anders, Di Pietro, Massimo, Wallet, Cedrick, Pozniak, Anton, Richert, Laura, Raffi, François
フォーマット: Artigo
言語:Inglês
出版事項: JAIDS Journal of Acquired Immune Deficiency Syndromes 2018
主題:
Clinical Science
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6250251/
https://ncbi.nlm.nih.gov/pubmed/30365452
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/QAI.0000000000001834
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料